BioCryst receives NIAID funding to conduct non-human primate study in Ebola virus
BioCryst announced that NIAID has awarded a contract modification for an additional $2.4 million to BioCryst to conduct a dose ranging efficacy study of an intramuscular formulation of BCX4430 in non-human primates as a treatment for Ebola virus disease. August 29, 2014